Abstract 372P
Background
Post concurrent chemo-radiotherapy (CRT) response assessment in locally advanced head and neck squamous cell carcinoma (HNSCC) has been critical to decide further treatment. Morphological response assessment was challenging due to prevailing post-radiation changes. While, molecular response methods have been encouraging. Nonetheless, heterogeneity in various molecular criteria need further clarifications. This study aims to propose and evaluate effectiveness of a semi-quantitative molecular response criterion to predict recurrence and survival.
Methods
A five points HAN-MI-RADS criterion was proposed by the two ≥ 15 yrs experienced Nuclear Medicine physicians and PET/CT of locally advanced HNSCC patients (n-83) post CRT at 3 months were reanalyzed. Histopathology examination (HPE) at 3 months and HPE/clinical/ imaging outcome on follow-up was taken as standard for disease status. Diagnostic statistics, disease free survival (DFI) and overall survival (OS) were calculated. A comparison with Hopkins score was also done with ROC analysis.
Results
Metastasis was developed in 11/83 patients (13.3%) at 3 months evaluation. Of 72 patients, 39, 2 and 31 patients had complete response (Score 1, 2, 3A), equivocal response (score 3B), and partial response (Score 4, 5) as per HAN-MI-RADS. Per patient sensitivity, specificity, PPV, NPV and accuracy for predicting loco-regional disease up to one year and two years was 93.3%, 92.5%, 90.3%, 94.9%, 92.9% and 84.9%, 91.9%, 90.3%, 87.2%, 88.6% respectively. One year and two years DFI for each HAN-MI-RADS score showed statistically significant difference while it was not for OS. The ROC curve analysis showed significantly better disease outcome predictability of HAN-MI-RADS (AUC 0.884) than Hopkins (AUC 0.699).
Conclusions
A five points HAN-MI-RADS criterion was found promising for response assessment with less equivocal results and statistically significant higher AUC than Hopkins for loco-regional recurrence prediction. Further, prospective studies analysis with larger patients will prove its clinical validity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract